These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
605 related articles for article (PubMed ID: 26143489)
1. Integration of prescription drug monitoring programs (PDMP) in pharmacy practice: Improving clinical decision-making and supporting a pharmacist's professional judgment. Norwood CW; Wright ER Res Social Adm Pharm; 2016; 12(2):257-66. PubMed ID: 26143489 [TBL] [Abstract][Full Text] [Related]
2. Promoting consistent use of prescription drug monitoring programs (PDMP) in outpatient pharmacies: Removing administrative barriers and increasing awareness of Rx drug abuse. Norwood CW; Wright ER Res Social Adm Pharm; 2016; 12(3):509-14. PubMed ID: 26329535 [TBL] [Abstract][Full Text] [Related]
3. Pharmacists' training, perceived roles, and actions associated with dispensing controlled substance prescriptions. Fleming ML; Barner JC; Brown CM; Shepherd MD; Strassels SA; Novak S J Am Pharm Assoc (2003); 2014; 54(3):241-50. PubMed ID: 24816350 [TBL] [Abstract][Full Text] [Related]
4. Utilization of prescription drug monitoring programs for prescribing and dispensing decisions: Results from a multi-site qualitative study. Freeman PR; Curran GM; Drummond KL; Martin BC; Teeter BS; Bradley K; Schoenberg N; Edlund MJ Res Social Adm Pharm; 2019 Jun; 15(6):754-760. PubMed ID: 30243575 [TBL] [Abstract][Full Text] [Related]
5. Clinical decision making involving prescription drug monitoring programs: A factorial, vignette-based study among student pharmacists. Tata V; Varisco TJ; Du N; Nguyen J; Haghparast P; Thornton JD J Am Pharm Assoc (2003); 2021; 61(3):316-324. PubMed ID: 33579594 [TBL] [Abstract][Full Text] [Related]
6. Using the theory of planned behavior to examine pharmacists' intention to utilize a prescription drug monitoring program database. Fleming ML; Barner JC; Brown CM; Shepherd MD; Strassels S; Novak S Res Social Adm Pharm; 2014; 10(2):285-96. PubMed ID: 23816495 [TBL] [Abstract][Full Text] [Related]
7. Prescription drug monitoring programs in community pharmacy: An exploration of pharmacist time requirements and labor cost. Upton C; Gernant SA; Rickles NM J Am Pharm Assoc (2003); 2020; 60(6):943-950. PubMed ID: 32792293 [TBL] [Abstract][Full Text] [Related]
8. Trends in Florida's Prescription Drug Monitoring Program registration and utilization: Implications for increasing voluntary use. Delcher C; Wang Y; Young HW; Goldberger BA; Schmidt S; Reisfield GM J Opioid Manag; 2017; 13(5):283-289. PubMed ID: 29199394 [TBL] [Abstract][Full Text] [Related]
9. How does use of a prescription monitoring program change pharmacy practice? Green TC; Mann MR; Bowman SE; Zaller N; Soto X; Gadea J; Cordy C; Kelly P; Friedmann PD J Am Pharm Assoc (2003); 2013; 53(3):273-81. PubMed ID: 23699676 [TBL] [Abstract][Full Text] [Related]
10. Educating Pharmacists on a Prescription Drug Monitoring Program. Fleming ML; Phan Y; Ferries EA; Hatfield MD J Pharm Pract; 2016 Dec; 29(6):543-548. PubMed ID: 25947949 [TBL] [Abstract][Full Text] [Related]
11. Examination of psychosocial predictors of Virginia pharmacists' intention to utilize a prescription drug monitoring program using the theory of planned behavior. Gavaza P; Fleming M; Barner JC Res Social Adm Pharm; 2014; 10(2):448-58. PubMed ID: 23953982 [TBL] [Abstract][Full Text] [Related]
12. The Prevalence of and Factors Associated With Receiving Concurrent Controlled Substance Prescriptions. Ferries EA; Gilson AM; Aparasu RR; Chen H; Johnson ML; Fleming ML Subst Use Misuse; 2017 Oct; 52(12):1639-1645. PubMed ID: 28557587 [TBL] [Abstract][Full Text] [Related]
13. Attitudes of Florida pharmacists toward implementing a state prescription drug monitoring program for controlled substances. Fass JA; Hardigan PC J Manag Care Pharm; 2011; 17(6):430-8. PubMed ID: 21787028 [TBL] [Abstract][Full Text] [Related]
14. Prescription Drug Monitoring Programs and Pharmacist Orientation Toward Dispensing Controlled Substances. Fendrich M; Bryan JK; Hooyer K Subst Use Misuse; 2018 Jul; 53(8):1324-1330. PubMed ID: 29297725 [TBL] [Abstract][Full Text] [Related]
15. Assessment of risk behaviors in patients with opioid prescriptions: A study of indiana's inspect data. Greene MS; Chambers RA; Yiannoutsos CT; Wright ER; Steele GK; Zollinger TW Am J Addict; 2017 Dec; 26(8):822-829. PubMed ID: 29143401 [TBL] [Abstract][Full Text] [Related]
16. Disclosure of Use and Abuse of Controlled Substances Among Psychiatric Outpatients. De Marco Centeno P; Baig M; Lee SE; Lane CJ; Lagomasino IT J Psychiatr Pract; 2015 Nov; 21(6):412-8. PubMed ID: 26554323 [TBL] [Abstract][Full Text] [Related]
17. Determinants of community pharmacists' quality of care: a population-based cohort study using pharmacy administrative claims data. Winslade N; Tamblyn R BMJ Open; 2017 Sep; 7(9):e015877. PubMed ID: 28939571 [TBL] [Abstract][Full Text] [Related]
18. Unsolicited Reporting to Prescribers of Opioid Analgesics by a State Prescription Drug Monitoring Program: An Observational Study with Matched Comparison Group. Young LD; Kreiner PW; Panas L Pain Med; 2018 Jul; 19(7):1396-1407. PubMed ID: 28383713 [TBL] [Abstract][Full Text] [Related]
19. Characteristics of state prescription drug monitoring programs: a state-by-state survey. Manasco AT; Griggs C; Leeds R; Langlois BK; Breaud AH; Mitchell PM; Weiner SG Pharmacoepidemiol Drug Saf; 2016 Jul; 25(7):847-51. PubMed ID: 27061342 [TBL] [Abstract][Full Text] [Related]
20. Predictors of pharmacists' likelihood to query prescription drug monitoring program databases. Arnold A; Bentley JP; Patel A; Holmes E J Am Pharm Assoc (2003); 2021; 61(5):614-622.e3. PubMed ID: 33994328 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]